Literature DB >> 26194309

Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans.

Paul S Aisen1, Ronald C Petersen2, Michael Donohue3, Michael W Weiner4.   

Abstract

INTRODUCTION: This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project.
METHODS: Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors.
RESULTS: The longitudinal data in ADNI-2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD). DISCUSSION: Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Cognitive assessment

Mesh:

Year:  2015        PMID: 26194309      PMCID: PMC4643840          DOI: 10.1016/j.jalz.2015.05.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  13 in total

Review 1.  Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Authors:  Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

3.  Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years.

Authors:  R Scott Mackin; Philip Insel; Paul S Aisen; Yonas E Geda; Michael W Weiner
Journal:  Int J Geriatr Psychiatry       Date:  2011-07-08       Impact factor: 3.485

4.  The relative efficiency of time-to-threshold and rate of change in longitudinal data.

Authors:  M C Donohue; A C Gamst; R G Thomas; R Xu; L Beckett; R C Petersen; M W Weiner; P Aisen
Journal:  Contemp Clin Trials       Date:  2011-04-30       Impact factor: 2.226

5.  Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.

Authors:  Rebecca E Amariglio; Michael C Donohue; Gad A Marshall; Dorene M Rentz; David P Salmon; Steven H Ferris; Stella Karantzoulis; Paul S Aisen; Reisa A Sperling
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

Review 6.  Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials.

Authors:  M C Donohue; P S Aisen
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

7.  Mild cognitive impairment due to Alzheimer disease in the community.

Authors:  Ronald C Petersen; Paul Aisen; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; David S Knopman; Michelle Mielke; Vernon S Pankratz; Rosebud Roberts; Walter A Rocca; Stephen Weigand; Michael Weiner; Heather Wiste; Clifford R Jack
Journal:  Ann Neurol       Date:  2013-08       Impact factor: 10.422

8.  The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment.

Authors:  R Scott Mackin; Philip Insel; Duygu Tosun; Susanne G Mueller; Norbert Schuff; Diana Truran-Sacrey; Sky T Raptentsetsang; Jun-Young Lee; Clifford R Jack; Paul S Aisen; Ronald C Petersen; Michael W Weiner
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

9.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

Authors:  Michael C Donohue; Reisa A Sperling; David P Salmon; Dorene M Rentz; Rema Raman; Ronald G Thomas; Michael Weiner; Paul S Aisen
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

10.  The A4 study: stopping AD before symptoms begin?

Authors:  Reisa A Sperling; Dorene M Rentz; Keith A Johnson; Jason Karlawish; Michael Donohue; David P Salmon; Paul Aisen
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

View more
  27 in total

1.  Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.

Authors:  Sebastian Palmqvist; Pontus Tideman; Nicholas Cullen; Henrik Zetterberg; Kaj Blennow; Jeffery L Dage; Erik Stomrud; Shorena Janelidze; Niklas Mattsson-Carlgren; Oskar Hansson
Journal:  Nat Med       Date:  2021-05-24       Impact factor: 53.440

2.  Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.

Authors:  David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

Review 3.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

4.  Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.

Authors:  Carey E Gleason; Derek Norton; Eric D Anderson; Michelle Wahoske; Danielle T Washington; Emre Umucu; Rebecca L Koscik; N Maritza Dowling; Sterling C Johnson; Cynthia M Carlsson; Sanjay Asthana
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Social isolation reinforces aging-related behavioral inflexibility by promoting neuronal necroptosis in basolateral amygdala.

Authors:  Juan Zhang; Dan Liu; Peng Fu; Zhi-Qiang Liu; Chuan Lai; Chun-Qing Yang; Kai Chen; Wen-Dai Bao; Fan Hu; Hui-Yun Du; Weili Yang; Jie Wang; Heng-Ye Man; Youming Lu; Ling-Qiang Zhu
Journal:  Mol Psychiatry       Date:  2022-07-15       Impact factor: 13.437

6.  Immunity gene IFITM3 variant: Relation to cognition and Alzheimer's disease pathology.

Authors:  Jung-Min Pyun; Young Ho Park; Angela Hodges; Jae-Won Jang; Paula J Bice; SangYun Kim; Andrew J Saykin; Kwangsik Nho
Journal:  Alzheimers Dement (Amst)       Date:  2022-06-21

7.  Spatial-Temporal Dependency Modeling and Network Hub Detection for Functional MRI Analysis via Convolutional-Recurrent Network.

Authors:  Mingliang Wang; Chunfeng Lian; Dongren Yao; Daoqiang Zhang; Mingxia Liu; Dinggang Shen
Journal:  IEEE Trans Biomed Eng       Date:  2019-12-06       Impact factor: 4.538

8.  Using Base Rate of Low Scores to Identify Progression from Amnestic Mild Cognitive Impairment to Alzheimer's Disease.

Authors:  Javier Oltra-Cucarella; Miriam Sánchez-SanSegundo; Darren M Lipnicki; Perminder S Sachdev; John D Crawford; José A Pérez-Vicente; Luis Cabello-Rodríguez; Rosario Ferrer-Cascales
Journal:  J Am Geriatr Soc       Date:  2018-05-10       Impact factor: 5.562

9.  Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.

Authors:  Shannon L Risacher; Wesley H Anderson; Arnaud Charil; Peter F Castelluccio; Sergey Shcherbinin; Andrew J Saykin; Adam J Schwarz
Journal:  Neurology       Date:  2017-10-25       Impact factor: 9.910

10.  Polygenic risk of Alzheimer disease is associated with early- and late-life processes.

Authors:  Elizabeth C Mormino; Reisa A Sperling; Avram J Holmes; Randy L Buckner; Philip L De Jager; Jordan W Smoller; Mert R Sabuncu
Journal:  Neurology       Date:  2016-07-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.